The FDA recently approved a sub-q therapy, Yeztugo (lenacapavir) from Gilead, indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating Yeztugo.
Yeztugo is the first injectable pre‑exposure prophylaxis (PrEP) given twice yearly via subcutaneous injection in the abdomen for adults and adolescents. Traditionally, HIV prevention relied on daily oral PrEP regimens, which have adherence challenges.
Lenacapavir’s twice‑annual dosing offers a near‑vaccine‑like convenience. Clinical trials showed near‑complete protection, zero infections in one cohort and dramatically fewer in another.
Market analysts suggest that the cost for Yeztugo will be set at approximately $28,000 per year.
Gilead did not comment on distribution details.
CLICK HERE to access prescribing information.
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
CLICK HERE to read the full article
